Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1618-1624

  McDonald, Paul C ^a   Oloumi, Arusha ^a   Mills, Julia ^a   Dobreva, Iveta ^a   Maidan, Mykola ^a   Gray, Virginia ^a   Wederell, Elizabeth D ^a   Bally, Marcel B ^a   Foster, Leonard J ^b   Dedhar, Shoukat ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; INTEGRIN LINKED KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; RICTOR PROTEIN; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; CYTOSKELETON; DOWN-REGULATION; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE; TANDEM MASS SPECTROMETRY; TRANSFECTION;

EID: 40949083412     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5869     Document Type: Article

References (24)

1. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005;5:51-63.
2. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
3. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
4. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006;16:1865-70.
5. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
6. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
7. Troussard AA, McDonald PC, Wederell ED, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 2006;66:393-403.
8. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrinlinked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001;276:27462-9.
9. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S. α(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 2003;22:1688-702.
10. Troussard AA, Mawji NM, Ong C, Mui A, St -Arnaud R, Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 2003;278:22374-8.
11. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005;65:1497-504.
12. Arregui CO, Carbonetto S, McKerracher L. Characterization of neural cell adhesion sites: point contacts are the sites of interaction between integrins and the cytoskeleton in PC12 cells. J Neurosci 1994;14:6967-77.
13. Chan QW, Howes CG, Foster LJ. Quantitative comparison of caste differences in honeybee hemolymph. Mol Cell Proteomics 2006;5:2252-62.
14. Schulze WX, Mann M. A novel proteomic screen for peptide-protein interactions. J Biol Chem 2004;279:10756-64.
15. Niewmierzycka A, Mills J, St -Arnaud R, Dedhar S, Reichardt LF. Integrin linked kinase (ILK) deletion from mouse cortex results in cortical lamination defects resembling cobblestone lissencephaly. J Neurosci 2005;25:7022-31.
16. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006;7:20-31.
17. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302.
18. Schroder W, Bushell G, Sculley T. The human stress-activated protein kinase-interacting 1 gene encodes JNK-binding proteins. Cell Signal 2005;17:761-7.
19. Schroder WA, Buck M, Cloonan N, et al. Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. Cell Signal 2007;19:1279-89.
20. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 2007;100:79-87.
21. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-37.
22. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
23. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
24. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.